linjc16/ctgov huggingface dataset:
Endosonography For Right Side Acute Intestinal Mal-Symptoms (EFRAIM- Study)

Study Overview
=================
Brief Summary
-----------------
Hypothesis: Endosonography (EUS) in a single setting is equivalent to the standard algorithm combining abdominal sonography, gastroscopy, endosonography in patients with acute right side abdominal pain. Patients with acute right side abdominal pain will be randomized in one of two groups. In each group all examinations (sonography, gastroscopy, endosonography) will be performed. The study group only defines the order of the examinations. Abdominal sonography will always be performed before endoscopic procedures. In group 1, gastroscopy is first followed by endosonography. In group 2 endosonography is first followed by gastroscopy. Two physicians will review all results of all examinations, patient charts as well as a follow up visit and establish a clinical diagnosis. Yield of the clinical diagnosis by EUS results alone will be compared to the yield by combined results of sonography, EGD and EUS.

Official Title
-----------------
Endosonography For Right Side Acute Intestinal Mal-Symptoms (EFRAIM- Study)

Conditions
-----------------
Abdominal Pain

Intervention / Treatment
-----------------
* Procedure: EGD
* Procedure: EUS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute right side abdominal pain willing participate study Exclusion Criteria: acute disease malignancy other disease which might cause discomfort

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: EGD<br>In this arm EGD will be performed before EUS | Procedure: EGD<br>* In this arm EGD will be performed before EUS.<br>* Other names: EUS: A standard diagnostic EUS will be performed.;|
| Active Comparator: EUS<br>In this arm, EUS will be performed before EGD. | Procedure: EUS<br>* In this arm EUS will be performed before EGD.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Yield of the clinical diagnosis by EUS results alone will be compared to the yield by combined results of sonography, EGD and EUS. |  | within the first week of complaints | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Calculate the time and cost savings and number of procedures for endosonography alone versus the combined approach of abd. sonography, gastroscopy and endosonography. |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endosonography, right side abdominal pain, Endosonography (diagnostic value in right side abdominal pain)
Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and effectiveness of three concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and an FDA approved anti-inflammatory agent in patients with ocular inflammation who have undergone cataract extraction with intra-ocular lens implantation.

Official Title
-----------------
A Multi-Center, Randomized, Double Masked, Placebo and Active Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of rEV131 2.5 Mg/mL, rEV131 1.25 Mg/mL, rEV131 0.625 Mg/mL, for the Treatment of Ocular Inflammation After Cataract Surgery

Conditions
-----------------
Ocular Inflammation

Intervention / Treatment
-----------------
* Drug: rEV131
* Drug: Prenisolone sodium phosphate 1.0%
* Drug: rEV131 vehicle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: be male or female who has undergone unilateral cataract extraction by phacoemulsification (PHACO) method with implantation of a posterior chamber intraocular lens Exclusion Criteria: have unstable glaucoma have an active bacterial and/or viral infection use any ocular or systemic anti-inflammatory agents within 1 week prior to enrollment and for the duration of the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: rEV131|nan|
|Drug: Prenisolone sodium phosphate 1.0%|nan|
|Drug: rEV131 vehicle|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer

Study Overview
=================
Brief Summary
-----------------
To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.

Official Title
-----------------
A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer

Conditions
-----------------
Metastatic Breast Cancer

Intervention / Treatment
-----------------
* Drug: Lipo-Dox


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically proved breast cancer with metastatic disease Exclusion Criteria: life expectancy less than 3 months.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lipo-Dox|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Phase II, Metastatic Breast Cancer
Neurological Effects of Chemotherapy and Radiation Therapy in Patients With Colon Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Learning about the long-term effects of chemotherapy and radiation therapy on brain function may help doctors plan cancer treatments. PURPOSE: This clinical trial is looking at the neurological effects of chemotherapy and radiation therapy in patients with colon cancer.

Detailed Description
-----------------
OBJECTIVES: Primary Identify the nature and long-term ramifications of CNS injury as a result of cancer treatment in patients with colon cancer. Secondary Analyze differences in cognitive measures and MRI data in these patients. Correlate MRI measures with cognitive performance in these patients. OUTLINE: Patients undergo cognitive performance assessment and MRI. PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.

Official Title
-----------------
Neurological Effects of Chemotherapy and Radiation Treatment: Colon Cancer

Conditions
-----------------
Cognitive/Functional Effects, Colorectal Cancer, Long-term Effects Secondary to Cancer Therapy in Adults

Intervention / Treatment
-----------------
* Procedure: cognitive assessment
* Procedure: magnetic resonance imaging
* Procedure: management of therapy complications


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of colon cancer Received chemotherapy and radiotherapy for colon cancer PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: See Disease Characteristics
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: cognitive assessment|nan|
|Procedure: magnetic resonance imaging|nan|
|Procedure: management of therapy complications|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nature and long-term ramifications of CNS injury as a result of cancer treatment |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in cognitive measures and MRI data |  |  | 
| Relationship between MRI measures and cognitive performance |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cognitive/functional effects, long-term effects secondary to cancer therapy in adults, recurrent colon cancer, stage I colon cancer, stage II colon cancer, stage III colon cancer, stage IV colon cancer
Quality Control Project of Stroke in Liaoning Province

Study Overview
=================
Brief Summary
-----------------
To reduce the incidence of stroke and standard the treatment of stroke in Liaoning Province, the present study should be conducted.

Official Title
-----------------
Quality Control Project of Secondary Prevention and Treatment of Stroke in Liaoning Province

Conditions
-----------------
Stroke, Ischemic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ischemic stroke Exclusion Criteria: disagreed patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Key Performance Indicator of Secondary Prevention of Stroke in Liaoning Province | The real KPI data such as intravenous thrombolysis number and quality, statin use, anti-platelet drugs, VET prevention, etc | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The results of Stroke prevention in Liaoning Province | The real data such as good neurological function outcome, stroke recurrence rate, death rate, etc. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prevention
Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)

Study Overview
=================
Brief Summary
-----------------
The main objective of the study is to estimate the proportion of children, born between the 06/04/2004 and the 17/004/2008, living around Neufchatel en Bray, vaccinated by MenBVac, with a serum bactericidal activity against B:14,P1-7,16 clone related to a protection (>= 4), before the fourth dose of MenBvac and after: 6 weeks and one year after the fourth dose.

Official Title
-----------------
Phase 3, Vaccinal Activity Assessment of MenBVac Against Neisseria Meningitidis B:14,P1.7,16 Strain in Child

Conditions
-----------------
Neisseria Meningitidis

Intervention / Treatment
-----------------
* Biological: MenBvac


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children born between 06/04/2004 and 17/04/2008, living in Neufchatel en Bray,and Having participated to the first study, children who Have to be Vaccinated MenBVac® for the four times, parental authority(ies)assent. Exclusion Criteria: no parental authority(ies)assent, no blood sample, impossibility of fourth vaccination, children yet vaccinated or non eligible for vaccination.

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bras A<br>children, born between the 06/04/2004 and the 17/04/2008, living around Neufchatel en Bray, before the fourth dose of MenBVac | Biological: MenBvac<br>* Blood test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaccine Immunity | Assessment of vaccine Immunity with measure of percentage of children who have hSBA title >= 4 six weeks after the fourth dose of vaccine | after the fourth dose of MenbVac | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neisseria meningitidis B:14, P1-7, 16, Serum bactericidal activity, OMV vaccine
The Effect of VOXX/eSmartr High Performance Technology on Sports Vision Ability

Study Overview
=================
Brief Summary
-----------------
This study is designed to compare the effect of Voxx/eSmartr technology on common measures of sports vision performance including (Hand-Eye Coordination/Reaction time, visual concentration and basic visual functions of size detection and contrast sensitivity). The study will be a randomized, prospective, double-blind design in order to determine the effect of this technology on a subject's sports vision ability.

Official Title
-----------------
The Effect of VOXX/eSmartr High Performance Technology on Sports Vision Ability

Conditions
-----------------
Vision, Binocular, Sports Medicine

Intervention / Treatment
-----------------
* Other: Voxx socks and sleeves


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria. Female or Male age 18-45 years of age Exercises at least once a week by self-report Physically able to complete the HEC/RT test (e.g. no shoulder or arm discomfort or limitation Exclusion Criteria. Member of a vulnerable population Visual or physical condition which precludes performing the physical or visual testing (e.g. strabismus, double vision, shoulder or arm pain or injury) Previous training in hand-eye coordination/reaction time or visual concentration History of double vision or strabismus Insufficient vision to drive an automobile in NY State

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: randomized, double blind, prospective
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Voxx socks and sleeves|participants will be tested with a true device as well as with a placebo device|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CoreScore | A measure of visual function scored on a linear scale fro +5 to -5, more positive scores are better | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hand-Eye Coordination/Reaction Time | A measure of how fast the subject reacts to a visual target with their hand, scored on milliseconds, faster the better | 1 day | 
| Neurotracker score | A measure of how correctly the subject can track multiple objects, scored from 0 to 5 with higher score being better | 1 day |
Early Lung Cancer Detection Using Computed Tomography

Study Overview
=================
Brief Summary
-----------------
Early detection of lung cancer may improve treatment outcomes. Risk factors have been identified, suggesting a population which might benefit from regular screening. Lung cancer screening using low-dose computed tomography (LDCT) has experienced a recent renaissance with reported sensitivity for detection of lung cancer of 2.7% in high-risk populations. The purpose of this study is to evaluate the utility of LCDT for the early diagnosis of lung cancer in Ontario.

Official Title
-----------------
Lung Cancer Screening in High-risk Smokers Using Low-dose Computed Tomography

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 55 years or older at least 10 pack-year history of smoking general good health Exclusion Criteria: any prior cancers except non-melanotic skin cancer

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung Cancer, Eary Diagnosis, Screening
Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the feasibility and efficacy of preoperative nimotuzumab injection combined with concurrent chemoradiotherapy for initially inoperable, locally advanced cervical cancer.

Official Title
-----------------
Preoperative Concurrent Chemoradiotherapy Combined With Nimotuzumab Injection for Locally Advanced Cervical Cancer: a Phase II Study

Conditions
-----------------
Locally Advanced Cervical Cancer

Intervention / Treatment
-----------------
* Other: Nimotuzumab+chemoradiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically or cytologically proven squamous cell cervical cancer Stages IB2-IIIB according to FIGO Staging System Age:18-75 ECOG<2 Normal bone marrow function Initial assessed and considered not candidates for operation Signed study-specific consent form Exclusion Criteria: Pregnant or lactating women Patients with other malignancies Patients who received radiotherapy or chemotherapy previously Presence of uncontrolled life-threatening illness Allergy to platinum or monoclonal antibody

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nimotuzumab+chemoradiotherapy<br> | Other: Nimotuzumab+chemoradiotherapy<br>* Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed. --------------------------------------------------------------------------------<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment related toxicities | Acute and chronic toxicities. | at 1 year | 
| Tumor response after preoperative treatment |  | assessed at 4-5 weeks after the completion of preoperative treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival |  | at 1 year | 
| Overall survival |  | at 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cervical cancer, Nimotuzumab, Intensity-modulated radiation therapy, Concurrent chemoradiotherapy
Heavy Metals' Influence on Early Pregnancy Through Oxidative Stress

Study Overview
=================
Brief Summary
-----------------
Patients with diagnosis of spontaneous abortion are enrolled in the cohort, in the cohort of patients who met the criteria, 3ml of whole blood intravenous and 5ml of urine were taken for heavy metal level examnation. Part of the villi tissue was sent for genetic testing, and the results were traced. In addition, about 10g of villi tissue was frozen for testing. Patients with normal genetic results of villi tissue will have villus samples go through oxidative stress level detection.

Detailed Description
-----------------
From May 1, 2019, patients with diagnosis of spontaneous abortion are enrolled in the cohort, exclusion criteria were: not long-term residents in Peking; Inconvenient for following up; Long-term of drug use; Cesarean section scar pregnancy and other high-risk pregnancy; Diagnosis of pregnancy beyond 12 weeks. In the cohort of patients who met the criteria, 3ml of whole blood intravenous and 5ml of urine were taken on the day of admission for curettage and suction, and the levels of heavy metals were tested. Part of the villi tissue was sent for genetic testing, and the results were traced. In addition, about 10g of villi tissue was frozen for testing. Patients with normal genetic results of villi tissue will have villus samples go through oxidative stress level detection.

Official Title
-----------------
Heavy Metals' Influence on Early Pregnancy Through Oxidative Stress

Conditions
-----------------
Spontaneous Abortion, Oxidative Stress

Intervention / Treatment
-----------------
* Diagnostic Test: Blood


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) the length of fetal bud is equal to or greater than 7 mm and there is no cardiac activity; 2) the maximum zh diameter of the pregnancy sac is equal to or greater than 25mm, and there is no fetal heart beat; 3) an embryo with no heartbeat at 2 weeks or more after ultrasound examination showing a pregnancy sac without yolk sac; 4) embryos without heartbeat for 11 days or longer after ultrasonography showed the yolk sac as a type pregnancy sac.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Blood|3ml blood|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oxident stress level |  | 1 year |